Praxis Precision Medicines is gearing up to launch a clinical trial of its experimental anti-seizure therapy relutrigine in people…
Articles by Marisa Wexler, MS
Stoke Therapeutics and Biogen are teaming up for the further development and potential commercialization of zorevunersen,…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to relutrigine, a treatment candidate for…
Targeting a heart protein called NaV1.6 may help prevent sudden death in adults with Dravet syndrome, a study in…
The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on higher doses of zorevunersen, an experimental…
Parents of children with Dravet syndrome in Spain say they don’t get enough support to help meet the emotional…
Although high-quality data are lacking, available evidence suggests that a procedure called vagus nerve stimulation (VNS) — which targets…
Having a child with Dravet syndrome affects the whole family, and it’s common for parents to feel burnt out…
Diacomit (stiripentol) may be more effective than other available Dravet syndrome treatments at reducing the frequency of seizures,…
Treatment with the experimental oral therapy bexicaserin led to sustained reductions in seizure frequency for children with Dravet syndrome…